Benjamin L. Palleiko Sells 7,627 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 7,627 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $9.75, for a total transaction of $74,363.25. Following the sale, the chief executive officer now owns 274,596 shares of the company’s stock, valued at approximately $2,677,311. This represents a 2.70 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $9.44 on Wednesday. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.39 and a 52 week high of $16.88. The firm’s 50-day simple moving average is $10.81 and its 200 day simple moving average is $11.80. The firm has a market cap of $466.52 million, a price-to-earnings ratio of -2.59 and a beta of 0.85.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. nVerses Capital LLC acquired a new stake in KalVista Pharmaceuticals during the second quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of KalVista Pharmaceuticals by 67.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after purchasing an additional 3,328 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth $126,000. SG Americas Securities LLC acquired a new position in KalVista Pharmaceuticals in the third quarter valued at about $153,000. Finally, Quest Partners LLC bought a new stake in KalVista Pharmaceuticals during the third quarter worth about $175,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).